Skip to main content
SpringerLink
Log in

Mesenchymal Stem Cell Transplantation for Systemic Lupus Erythematosus

  • Chapter
  • First Online:
Essentials of Mesenchymal Stem Cell Biology and Its Clinical Translation

  • 1556 Accesses

Abstract

Recently, a substantial progress has been made in the field of mesenchymal stem cell transplantation (MSCT). Experimental and clinical data suggest that MSCT has been a promising therapy strategy for severe and refractory systemic lupus erythematosus (SLE). From March, 2007 to now, more than 210 SLE patients in the world have received the MSCT. Over 90 % of the transplantations were carried out in the Affiliated Drum Tower Hospital of Nanjing University Medical School in China. The reported main types of cell source are allogenic bone marrow (BM, 21 %) and umbilical cord (UC, 78 %) and autologous BM (1 %). The infused MSCs dose was 1 × 106 per kg body weight. The outcome measures, such as disease activity, 24-h proteinuria, serologic features and even glomerular filtration rate have improved significantly. In addition, no serious adverse events related to MSCT were reported so far. Double UC-MSCT could not enhance therapeutic effect compared with single transplantation in refractory SLE. This chapter will review the rationale, progress and perspectives of MSCT in treatment of SLE.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418:41–9.

    Article  PubMed  CAS  Google Scholar 

  2. Debayon P, Samuel SM, Maulik N. Mesenchymal stem cell: present challenges and prospective cellular cardiomyoplasty approaches for myocardial regeneration. Antioxid Redox Signal. 2009;11:1841–55.

    Article  Google Scholar 

  3. Ju S, Teng GJ, Lu H, Jin J, Zhang Y, Zhang A, Ni Y. In vivo differentiation of magnetically labeled mesenchymal stem cells into hepatocytes for cell therapy to repair damaged liver. Invest Radiol. 2010;45(10):625–33.

    Article  PubMed  Google Scholar 

  4. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110:3499–506.

    Article  PubMed  CAS  Google Scholar 

  5. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, Mao N. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood. 2005;105:4120–6.

    Article  PubMed  CAS  Google Scholar 

  6. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells. 2006;24:74–85.

    Article  PubMed  Google Scholar 

  7. Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol. 2003;171:3426–34.

    PubMed  CAS  Google Scholar 

  8. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8(9):726–36.

    Article  PubMed  CAS  Google Scholar 

  9. Selmani Z, Naji A, Gaiffe E, Obert L, Tiberghien P, Rouas-Freiss N, Carosella ED, Deschaseaux F. HLA-G is a crucial immunosuppressive molecule secreted by adult human mesenchymal stem cells. Transplantation. 2009;87(9 Suppl):S62–6.

    Article  PubMed  CAS  Google Scholar 

  10. Soleymaninejadian E, Pramanik K, Samadian E. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am J Reprod Immunol. 2012;67(1):1–8.

    Article  PubMed  CAS  Google Scholar 

  11. Chin SP, Poey AC, Wong CY, Chang SK, Teh W, Mohr TJ, Cheong SK. Cryopreserved mesenchymal stromal cell treatment is safe and feasible for severe dilated ischemic cardiomyopathy. Cytotherapy. 2010;12(1):31–7.

    Article  PubMed  CAS  Google Scholar 

  12. Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS, Wu SJ, Luo CW, Guo R, Ling W, Deng CX, Liao PJ, Xiang AP. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant. 2010;45(12):1732–40.

    Article  PubMed  CAS  Google Scholar 

  13. Sasaki Y, Honmou O. Bone marrow stem cell therapy for stroke. Nihon Rinsho. 2011;69(12):2203–8.

    PubMed  Google Scholar 

  14. Spagnoli A, Longobardi L, O’Rear L. Cartilage disorders: potential therapeutic use of mesenchymal stem cells. Endocr Dev. 2005;9:17–30.

    Article  PubMed  CAS  Google Scholar 

  15. Cucchiarini M, Venkatesan JK, Ekici M, Schmitt G, Madry H. Human mesenchymal stem cells overexpressing therapeutic genes: from basic science to clinical applications for articular cartilage repair. Biomed Mater Eng. 2012;22(4):197–208.

    PubMed  Google Scholar 

  16. Ikehara S, Kawamura M, Takao F, Inaba M, Yasumizu R, Than S, Hisha H, Sugiura K, Koide Y, Yoshida TO, et al. Organ-specific and systemic autoimmune diseases originate from defects in hematopoietic stem cells. Proc Natl Acad Sci USA. 1990;87:8341–4.

    Article  PubMed  CAS  Google Scholar 

  17. Ikehara S, Yasumizu R, Inaba M, Izui S, Hayakawa K, Sekita K, Toki J, Sugiura K, Iwai H, Nakamura T, et al. Long-term observations of autoimmune-prone mice treated for autoimmune disease by allogeneic bone marrow transplantation. Proc Natl Acad Sci USA. 1989;86:3306–10.

    Article  PubMed  CAS  Google Scholar 

  18. Yin JA, Jowitt SN. Resolution of immune-mediated diseases following allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant. 1992;9(1):31–3.

    PubMed  CAS  Google Scholar 

  19. Ikehara S, Inaba M, Yasumizu R, Nagata N, Toki J, Hisha H, Sugiura K, Oyaizu N, Kawamura M, Than S, et al. Autoimmune diseases as stem cell disorders. Tohoku J Exp Med. 1994;173(1):141–55.

    Article  PubMed  CAS  Google Scholar 

  20. Kushida T, Inaba M, Hisha H, Ichioka N, Esumi T, Ogawa R, Iida H, Ikehara S. Crucial role of donor-derived stromal cells in successful treatment for intractable autoimmune diseases in mrl/lpr mice by BMT via portal vein. Stem Cells. 2001;19(3):226–35.

    Article  PubMed  CAS  Google Scholar 

  21. Papadaki HA, Boumpas DT, Gibson FM, Jayne DR, Axford JS, Gordon-Smith EC, Marsh JC, Eliopoulos GD. Increased apoptosis of bone marrow CD34(+) cells and impaired function of bone marrow stromal cells in patients with systemic lupus erythematosus. Br J Haematol. 2001;115:167–74.

    Article  PubMed  CAS  Google Scholar 

  22. Sun LY, Zhang HY, Feng XB, Hou YY, Lu LW, Fan LM. Abnormality of bone marrow-derived stem cell in patients with systemic lupus erythematosus. Lupus. 2007;16(2):121–8.

    Article  PubMed  CAS  Google Scholar 

  23. Nie Y, Lau C, Lie A, Chan G, Mok M. Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus. 2010;19:850–9.

    Article  PubMed  CAS  Google Scholar 

  24. El-Badri NS, Hakki A, Ferrari A, Shamekh R, Good RA. Autoimmune disease: is it a disorder of the microenvironment? Immunol Res. 2008;41(1):79–86.

    Article  PubMed  CAS  Google Scholar 

  25. Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, Xu T, Le A, Shi S. Mesenchymal stem cell transplantation reverses multi-organ dysfunction in systemic lupus erythematosus mice and humans. Stem Cells. 2009;27:1421–32.

    Article  PubMed  CAS  Google Scholar 

  26. Tang Y, Xie H, Chen J, Geng L, Chen H, Li X, Hou Y, Lu L, Shi S, Zeng X, Sun L. Activated NF-kB in bone marrow mesenchymal stem cells from SLE patients inhibits osteogenic differentiation through down-regulating Smad signaling. Stem Cells Dev. 2013;22(4):668–78.

    Article  PubMed  CAS  Google Scholar 

  27. Shi D, Li X, Sun L. High oxidation status induced the rearrangement of F-actin cytoskeleton of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus via downregulation of RhoA signaling pathway. Int J Rheum Dis. 2012;15 Suppl 1:26–8.

    CAS  Google Scholar 

  28. Li X, Liu L, Meng D, Wang D, Zhang J, Shi D, Liu H, Xu H, Lu L, Sun L. Enhanced apoptosis and senescence of bone-marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Stem Cells Dev. 2012;21(13):2387–94.

    Article  PubMed  CAS  Google Scholar 

  29. Gu Z, Cao X, Jiang J, Li L, Da Z, Liu H, Cheng C. Upregulation of p16(INK4A) promotes cellular senescence of bone marrow-derived mesenchymal stem cells from systemic lupus erythematosus patients. Cell Signal. 2012;24(12):2307–14.

    Article  PubMed  CAS  Google Scholar 

  30. Tang Y, Ma X, Zhang H, Gu Z, Hou Y, Gilkeson GS, Lu L, Zeng X, Sun L. Gene expression profile reveals abnormalities of multiple signaling pathways in mesenchymal stem cell derived from patients with systemic lupus erythematosus. Clin Dev Immunol. 2012;2012:826182.

    Article  PubMed  Google Scholar 

  31. Zhou K, Zhang H, Jin O, Feng X, Yao G, Hou Y, Sun L. Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol. 2008;5(6):417–24.

    Article  PubMed  Google Scholar 

  32. Gu F, Molano I, Ruiz P, Sun L, Gilkeson GS. Differential effect of allogeneic versus syngeneic mesenchymal stem cell transplantation in MRL/lpr and (NZB/NZW)F1 mice. Clin Immunol. 2012;145(2):142–52.

    Article  PubMed  CAS  Google Scholar 

  33. Carrion F, Nova E, Ruiz C, Diaz F, Inostroza C, Rojo D, Mönckeberg G, Figueroa FE. Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus. 2010;19(3):317–22.

    Article  PubMed  CAS  Google Scholar 

  34. Liang J, Zhang H, Hua B, Wang H, Lu L, Shi S, Hou Y, Zeng X, Gilkeson GS, Sun L. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis. 2010;69(8):1423–9.

    Article  PubMed  Google Scholar 

  35. Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, Gong W, Han ZB, Xu ZS, Lu YX, Liu D, Chen ZZ, Han ZC. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica. 2006;91:1017–26.

    PubMed  CAS  Google Scholar 

  36. Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H, Hua B, Liu B, Ye S, Hu X, Xu W, Zeng X, Hou Y, Gilkeson GS, Silver RM, Lu L, Shi S. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 2010;62(8):2467–75.

    Article  PubMed  CAS  Google Scholar 

  37. Sato K, Ozaki K, Mori M, Muroi K, Ozawa K. Mesenchymal stromal cells for graft-versus-host disease: basic aspects and clinical outcomes. J Clin Exp Hematop. 2010;50(2):79–89.

    Article  PubMed  Google Scholar 

  38. Toubai T, Paczesny S, Shono Y, Tanaka J, Lowler KP, Malter CT, Kasai M, Imamura M. Mesenchymal stem cells for treatment and prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation. Curr Stem Cell Res Ther. 2009;4(4):252–9.

    Article  PubMed  CAS  Google Scholar 

  39. Wang D, Akiyama K, Zhang H, Yamaza T, Li X, Feng X, Wang H, Hua B, Liu B, Xu H, Chen W, Shi S, Sun L. Double allogenic mesenchymal stem cells transplantations could not enhance therapeutic effect compared with single transplantation in systemic lupus erythematosus. Clin Dev Immunol. 2012;2012:273291.

    PubMed  Google Scholar 

  40. Jeong JO, Han JW, Kim JM, Cho HJ, Park C, Lee N, Kim DW, Yoon YS. Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy. Circ Res. 2011;108(11):1340–7.

    Article  PubMed  CAS  Google Scholar 

  41. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, Noël D, Jorgensen C. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 2003;102(10):3837–44.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology and Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, Jiangsu, 210008, P. R. China

    Lingyun Sun

Authors
  1. Lingyun Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lingyun Sun .

Editor information

Editors and Affiliations

  1. Chinese Academy of Medical Sciences and Peking Union Medical College, Center of Excellence in Tissue Engineering, Institute of Basic Medical Sciences and School of Basic Medicine, 5 Dong Dan San Tiao, Beijing, 100005, China, People's Republic

    Robert Chunhua Zhao

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Sun, L. (2013). Mesenchymal Stem Cell Transplantation for Systemic Lupus Erythematosus. In: Zhao, R. (eds) Essentials of Mesenchymal Stem Cell Biology and Its Clinical Translation. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6716-4_17

Download citation

Publish with us

Policies and ethics

Search

Navigation